Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
Wipro’s agents for Agentforce will elevate efficiency and customer satisfaction at healthcare companies
Nadda noted that TB treatment coverage in India has increased from 59% to 85%
Prior to joining Neuland, Deshmukh held several key positions at Cipla
Over the last two years, Lupin has showcased exceptional improvement in its EcoVadis scoring
Empamore is poised to make a significant impact by offering high-quality treatment at an affordable price point, empowering millions of Indians to take control of their health
Experts urge early detection & better access to care
Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant
Overall investment in the US facility is estimated around US$50 million
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
Subscribe To Our Newsletter & Stay Updated
